A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure

• Published in: Curēus (Palo Alto, CA) CA), 2024-12, Vol.16 (12), p.e76519
• Main Authors: Gul, Ushna, Aung, Thandar, Martin, Mehwish, Farrukh, Daanyal N, Shah, Pari C, Lovely, Zeenia S, Marroquín León, Esaúl, Alansaari, Mohamed, Maini, Shriya, Fariduddin, Muddasir Mohammed, Ullah, Ashraf, Nazir, Zahra
• Format: Article
• Language: English
• Subjects: Cardiology; Internal Medicine; Other
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.76519

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed to manage type 2 diabetes mellitus. Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated. This narrative review explores the metabolic effects of GLP-1 RAs in weight management, blood glucose, cardiovascular health, lipid profiles, and blood pressure. Data were collected by comparing GLP-1 RAs, such as semaglutide, liraglutide, tripeptide, and exenatide, as well as comparing them to a baseline treatment group. GLP-1 RAs have shown consistent results in managing blood glucose levels by lowering HbA1c with minimal hypoglycemic risk and increasing insulin production and synthesis. GLP-1 RAs have been found to improve overall cardiovascular health and reduce major adverse cardiovascular events (MACE) by improving the endothelial function of the vasculature and lowering ANP (atrial natriuretic peptide) production, leading to reduced blood pressure. In addition to the cardiovascular benefits, GLP-1 RAs have a varying effect on lipid profiles, finding statistically significant results for low-density lipoprotein cholesterol levels. In conjunction with all the effects, GLP-1 RAs have been found to lower weight and aid in weight management.